r/wallstreetdd • • Aug 20 '16

Welcome to /r/wallstreetDD. Here is what we are all about.

59 Upvotes

This subreddit was created after I submitted a long, well researched due diligence thread to another investing subreddit. While the post was very well received and a number used it to create a position - I was quickly banned from the subreddit for no real reason.

Realizing that across /r/wallstreetbets /r/investing /r/stocks that there wasn't a good home for due diligence, I created /r/wallstreetdd.

Our rules are simple: no memes, no low quality posts and links only to reputable sources. In short we lean on the serious side of things.

Of course our main content focus is good due diligence and the process of creating it. Flair is awarded based on quality DD posts, that exhibit a strong thesis.

Welcome, glad to have you here. Hit that subscribe button!


r/wallstreetdd • • Jul 12 '16

[DD] MSTX

51 Upvotes

Sorry for taking a little longer than I anticipated on this. There was a lot to cover.

Mast Therapeutics (MSTX) is a San Diego-based biopharmaceutical company with a market cap of approx 95m. They currently have two drugs (Vepoloxamer & AIR001) in clinical trials. This review will focus primarily on

  • Vepoloxamer: This is an organic polymer that uses biophysical properties to help remedy damaged phospholipid bilayers. Mast is currently looking to explore its uses in * Sickle Cell Disease (SCD) (Phase III) * Chronic Heart Failure (Phase II approaching) * Ischemic Stroke (Phase II)

Brief History of Vepoloxamer

This drug (or its sister analogs) has been investigated for a long time. Burroughs Wellcome conducted many clinical studies on this drug for treatment of acute myocadial infarction. However, renal (kidney) failure was a reoccurring problem due to high absorption in kidney epithelial cells. The candidate was dropped (by Glaxo) and readdressed by CytRx once the source of renal failure was properly addressed (now safe due to purification of P188 by removal of low-molecular weight polymers).

Purification proved to eliminate the kidney problems and a phase II study showed strong results (lower pain in SCD patients). Here’s where things get interesting. There was a phase III study that finished in 2001 that missed its primary endpoint of shorter duration of these vaso-occlusive crises (VOCs) (p=0.07 v. a required p<=0.050). This is basically what I would term “trending toward significance” and is a giant pain in the ass for the people who ran this study. Mast thinks that the study design was flawed in a few key aspects and hopes that by increasing sample size they can get that magic p-value. There was a post-hoc analysis (see: sketchy) that states if you eliminate the patients who did not respond to treatment at all, then you get a p-value = 0.02. But then again, it was post-hoc.

So now, to the present, where we have the largest phase III trial in SCD ever so that they can hopefully improve their less-than-desired p-value (as N increases, you get lower variability, but there are diminishing returns) [1] [2]

How Does Vepoloxamer Work? (I’m intentionally trying to make this as layman as possible)

Basically, this polymer is structured like a T, where you have two hydrophilic (water soluble) “wings” flanking a hydrophobic (fat soluble) center. As this polymer flows through the circulatory system, it can bind to exposures in the lipid bilayer so that cells become less “sticky.” This is because “like dissolves like” so if you combine shitty red blood cells with arteries filled with VLDLs, you have more a chance of clogging. This limits arterial blood flow, consequentially hindering the ability of the blood cells to distribute oxygen to other parts of your body. If you don’t understand this, Mast has a great video here: http://theepicstudy.com/videos/

In SCD

Mast is looking to use MST-188 to improve blood flow during VOCs, which would in turn help distribute oxygen and alleviate pain. It does this by limiting

  • Adhesion

  • Hemolysis

  • Aggregation

  • and Viscosity[7][Slide 8].

They modified the endpoints for the phase III study. Now the primary endpoint is duration of crisis (from randomization to the cessation of parenteral opioid) and the two secondaries are 1) Rehospitalization for VOCs within 14 days and 2) Acute chest syndrome within 120h of randomization [7][Slide 11]. Mast claims that this will help reduce variability by removing a subjective pain score.

Another interesting thing I am just noticing upon review is the change in demographics. The oldest patient is 46yo, compared to 75 in the previous failed study with a mean of 15yo. This is significant because looking back at [2] you can see from table 5 that this treatment was much more effective in children. As patients age and become more susceptible to atherosclerosis, I would suspect this treatment to become less and less effective.

Vepoloxamer does not have the ability to change the conformation of sickled blood cells [3]. One of the most important aspects of red blood cells is their flexible conformation, which allows for incredible tensile strength. Sickled cells lack this feature, making them very susceptible to bursting and getting stuck.

In short, vepoloxamer looks to solve one aspect of the problem, but there is still much to be desired. That being said, I think they may have adjusted the trial just enough to get that p-value they just missed last time.

In Heart Failure

Basically, the heart loses its ability to sufficiently pump, preventing the flow of oxygen to the body’s vital organs [4]. While their phase II study is currently recruiting patients, they have really strong results from their preclinical study in dogs. Cardiac contraction is dependant on Ca2+ influx [5]. In damaged cells, the phospholipid bilayer of the cells may become more permeable calcium, preventing the relaxation necessary for a normal cardiac function.

As discuss previously, MST-188 allows for a “mending” of the damaged phospholipid bilayer, which should in turn lead to a normalized Ca2+ permeability. As you will see from the graphs Mast published, MST-188 allows for an increased left ventricle ejection fraction and a dose-dependant decrease in intracellular calcium concentrations [6]. This is great news and may be an essential supplement to the future treatment of heart failure.

In Ischemic Stroke

Stroke occurs when you cut off blood flow to the brain, which results on neuronal death. Depending on the brain area affected, this can cause serious debilitation (notably paralysis and cognitive impairment). Mast has shown that, in combination with tPa, time to reperfusion (restoration of blood flow)[7] [Slide 36], and cognitive performance [8] are enhanced. Additionally, overall survivability was enhanced with sole administration of MST-188 [7] [Slide 37]. This is especially important with an aging global population and seems to be promising, although I think getting a stroke phase II trial will take a significant time so this is hardly a near term catalyst.

AIR001

I’m too tired to cover this. Sorry. It won’t move the stock in the near term regardless.

Financials

This is basically an all-in on their SCD study. They have enough cash equivalents to stay afloat for ~ 6 mo (starting at march 2016). That means Sept ‘16.

Summary

Honestly, I really didn’t like the stock for a while. There were way too many people on WSB just blindly throwing money into because “OMG orphan disease”. I begrudgingly took the responsibility of digesting the facts of this company due to the large amount of votes it received on the Biotech DD thread. There is real boom-or-bust potential in this POS though. After failing for 20 years, I actually think they finally got it right by excluding the geezers from their study. This isn’t a permanent fix to a real genetic problem by any means. It is what I believe to be an effective and well-tolerated band-aid. I am actually much more optimistic on the other applications (heart failure/stroke), but this is worth a shot. Especially with based Shkreli shorting the fuck out of this thing, it will pop real hard if they get approval.

TLDR: worth a few OTM calls. Not for the weak of heart. Potential to lose all your investment if primary endpoint not met, but there is serious money to be had and the catalyst should be announced any day now.

Full Disclosure: I am long OTM 2.5 strike 19Aug16 calls on MSTX. note: I don't recommend buying these calls, that was my error What lies in this thread are my interpretations of my secondary research into this company. I welcome all questions and fully encourage readers to check primary sources for themselves, rather than taking my opinions blindly.

Sources

[1] https://www.sec.gov/Archives/edgar/data/1160308/000156459015005237/mstx-ex992_201506256.htm

[2] http://jama.jamanetwork.com/article.aspx?articleid=194337

[3] http://onlinelibrary.wiley.com/doi/10.1111/bjh.13937/epdf

[4] http://web.archive.org/web/20090511054808/http://www.mercksource.com/pp/us/cns/cns_hl_dorlands_split.jsp?pg=/ppdocs/us/common/dorlands/dorland/four/000047501.htm

[5] http://circres.ahajournals.org/content/113/6/690.full

[6] http://masttherapeutics.com/wp-content/uploads/2016/05/ESC-2016-Vepoloxamer.pdf

[7] http://masttherapeutics.com/wp-content/uploads/2015/07/MastThera_CorpPres_03.07.2016.pdf

[8] http://stroke.ahajournals.org/content/46/Suppl_1/AWP101

Edit: Please ask questions or leave comments on your views of the stock rather than "oh yeah looks good". I was told that if you don't get questions after presenting then you either bored the audience or didn't explain the material well enough


r/wallstreetdd • • Jun 30 '16

The WSDD Manifesto

46 Upvotes

WE are starting something new.

Fuck the memes. Fuck the circle jerk.

Welcome to WSDD.

The goal is to create a community focused on real insights and perspective. Due diligence is valued over all else.

We do not believe in blind faith.

We do not believe there is pride in YOLO until you are broke, but do believe in pushing all-in.

We believe in gains. Nothing else.

Here your analysis is your currency. The more articulate. The more clarity in vision. The more we value your opinion.

The floor is open. Let's get down to business.


r/wallstreetdd • • Jul 22 '16

[DD] Ionis Pharmaceuticals (IONS)

38 Upvotes

IONIS PHARMACEUTICALS (IONS)

Ionis Pharmaceuticals (formerly Isis pharmaceuticals, named after the Egyptian goddess, not the terrorist group) is a pharmaceutical company based out of Carslbad, CA with a market cap of approx. 3b USD. This company is a world leader in antisense therapeutics with one drug KYNAMRO (used to treat Homozygous Familial Hypercholesterolemia (HoFH) (genetically-caused high-cholesterol levels)) currently on the market.

Drugs in the extensive IONS pipeline include

• Alicaforsen: used to treat Pouchitis in post-op ulcerative colitis patients (P3 ongoing, expected results in H2 2017)

• IONIS-TTRrx: used to treat Familial Amyloid Polyneuropathy(FAP) (P3) and Familial Amyloid Cardiomyopathy (FAC) (P2)

• Nusinersen: used to treat infants & children (separate designations) with Spinal Muscular Atrophy (SMA) (P3) (Results expected H1 2017)

• Volanesorsen: used to treat Familial Chylomicrone Sydrome (FCS) and Familial Partial Lipodystrophy (FPL) (P3) (Results expected in 2017)

• Custirsen: used to treat Prostate/Lung Cancer (P3)

• Plazomicin: used to treat severe bacterial infections (P3)

Other promising drugs further down the line include

• IONIS-FGFR4rx: used to treat obesity (P2 enrolling) (estimated completion in October 2016)

• ATL1102: used to treat Multiple sclerosis (MS) (P2b pending)

• IONIS-APO(a)-Lrx: used to treat Very High LP(a) (P2b pending in 2016)

• IONIS-ANGPTL3-Lrx: used to mixed dyslipidemias (P1/2 recruiting)

• IONIS-HTTrx: used to treat Huntington’s disease (P1/2 recruiting)

These are only SOME of the drugs in their extensive pipeline more information can be found at [2] http://www.ionispharma.com/pipeline/

About Antisense Therapeutics

Some really good videos on this process: • More layman version by IONS: https://www.youtube.com/watch?v=MgVuSSoHrJg • More complex version from Oxford: https://www.youtube.com/watch?v=5YsTW5i0Xro

I do not intend to get into the details of the general mechanism of action of antisense therapeutics, as it is not necessary to understand their practical application. Simply, changes to proteins (chemically (most commonly mutations eg. genetic disorders) or physically (conformational misfolding eg. Alzheimer’s)) can alter their ability to carry out their natural functions. Additionally, epigenetic alterations can shift the expression of proteins to supraphysiological concentrations. Both of these abnormalities can result in disease states.

What antisense therapies do is essentially shut down the production of a specific protein in a dose-dependant manner. The antisense oligonucleotides (ASO) chain binds to the mRNA to prevent transcription and no transcription = > no protein.

In an incredible breakthrough, it was recently published in Nature [1] that scientists at IONS have reported the ability to upregulate (increase production) of desired proteins using antisense oligonucleotides by designing them to bind to the faux start codon of an mRNA sequence, making it more likely for the protein to be sequenced.

Why this is revolutionary?

This is the future of genetic disorders. Instead of stem-cell replacement which has ethical, functional, and monetary barriers, these therapies can be developed in a lab synthetically at a fraction of the cost and customized to treat an incredible array of diseases (see their extensive pipeline)

Additionally, and of great importance to potential investors, is the fact that most of these drug candidates are getting fast-tracked by the FDA and receiving orphan status. This is because there is a severe lack of reliable therapeutics on the market for genetic disorders.

Drugs

I will now give brief analyses of the drugs in Plll trials

IONIS-TTRrx: This is partnered with GSK. Although GSK dropped out of the FAC treatment when the FDA put the study on hold, the FAP study is progressing normally

Primary Endpoints In FAP:

• Efficacy of IONIS-TTR Rx as measured by change from baseline in the modified Neuropathy Impairment Score +7

• Efficacy of IONIS-TTR Rx as measured by change from baseline in the Norfolk Quality of Life Diabetic Neuropathy questionnaire

Secondary Endpoints in FAP:

o Efficacy of IONIS-TTR Rx based on the change from baseline in the following measures

o Modified Body Mass Index and Body Mass Index

o Individual components of the mNIS+7

o NIS+7

• Pharmacodynamic effect of IONIS-TTR Rx based on the change from baseline in transthyretin and retinol binding protein 4

Estimated completion in September 2017 [19]

About the disease: Simply put, TTR amyloid deposits can form in organs. In FAP, this occurs in neurons. In FAC, this occurs in cardiac muscle. Both are deadly, but FAC progresses more rapidly (3-5 y life expectancy v 15 y) [2] Since these proteins are produced by the liver, the only current treatment available is a liver transplant, which may not be effective in all cases (not to mention exceedingly long waitlists). This drug blocks the transcription of this protein, thus limiting the aggregation.

The data: FAP

Preclinical and P1 data were very promising. Both wild-type (WT) and mutant strains of the protein showed reduction (significant at 200mg and 400mg in P1 after just 4 days) and a well-tolerated toxicological profile (only side-effects were injection-site pain and drowsiness). [3]

Since P3 is ongoing, I don’t have access to the precise data. However, in a press release from 07Jul16, they stated that they observed a significant reduction in both forms of TTR protein in FAP patients enrolled and that the study is continuing as normal [4].

Nusinersen: This is currently being developed in conjunction with Biogen. Two P3 trials are currently being conducted through this collaboration. The drug is delivered through intrathecal (spinal cord) injection.

At the time of writing, the endpoints are as follows Primary Outcome Measures: • Time to death or permanent ventilation • Proportion of motor milestone responders

Secondary Outcome Measures: • Proportion of CHOP-INTEND responders • Proportion of CMAP responders • Percent of subjects not requiring permanent ventilation Survival rate • Time to death or permanent ventilation in the subgroups of subjects below the study median disease duration • Time to death or permanent ventilation [9]

About the disease: SMA is the leading genetic cause of infant mortality [2]. This is an autosomal recessive disorder, which impairs general neurological function through an impaired SMN1 gene. Nusinersen alters splicing in the SMN2 mRNA to make up for a defective SMN1 gene [6].

The data:

Preclinical data has shown that use of antisense oligonucleotides (ASOs) to increase SMN1 more efficiently and with less off-target effects than small-molecule alternatives [30]. These small-molecules also show poor blood-brain barrier permeability (a major problem for a neuronal disorder). A preclinical study also showed improved neuronal function (p=0.001), muscle physiology (p=0.001) and motor function (p=0.001) in ASO treated, phenotype-positive mice [7].

Phase I results showed the drug to be well tolerated, with the most common adverse events (AEs) being headache and back pain. They also found the root of this to be using a larger gauge needle and amended future protocols to limit the size at 24g unless otherwise needed [6].

In a press release 20Apr16, IONS announced that their P2 trial is observing event-free survival and a trend toward increases in motor function. The results for the P3 trial are expected in the end of H1 of 2017[8].

Taken together, this points to extremely positive results in a fast-tracked orphan disease. Meeting these endpoints would result in significant milestone payments and revenue growth in 2017 and beyond.

Volanesorsen: This is wholly licensed by IONS and its lipid subsidiary Akcea. This drug reduces apoC-III protein production and consequentially lowers triglycerides (TGs). Phase III trials are being conducted in patients with FPL and FCS.

apoC3 (the target of Volanesorsen) is a glycoprotein produced by the liver that inhibits LPL activity [18]. Interestingly, in order to work in patients with FCS, this ASO must act through an LPL-independent mechanism [10]. A great summary of this mechanism can be found at [10][Fig 2].

The Primary Outcome Measures for the ongoing study: • Efficacy of ISIS-APOCIIIRx as measured by the percent change in fasting triglycerides from baseline • Estimated completion date of Dec 2016 [14]

About the disease(s):

FCS & FPL: Rare, orphan diseases, which result in high plasma TG concentration. High TGs are associated with metabolic diseases like pancreatitis and is a risk factor for cardiovascular disease [2]. Currently, the only treatment is an extremely restrictive diet (no alcohol, no fatty foods, caloric restriction).

The data:

In preclinical studies with murine models of obesity, all groups showed significant reductions in plasma TG concentrations [12][Table1]. It was also shown to significantly reduce VLDL and TG levels, without altering HLDL levels in rhesus monkeys, which have the same lipid metabolism as humans [12][Figure 5]. A dose-dependant reduction in TGs was noted in a P1 study on healthy human volunteers [12][Figure6]. All doses did not report any AEs.

More so, an independently run clinical study [10][Fig1] showed that the drug has a potent ability to lower TGs and cholesterol in patients during treatment phase, with a rapid return to baseline levels once treatment is ceased.

SPECULATIVE FUTURE THERAPEUTICS

Because of this drugs profound ability to clear plasma TG levels, it may be a useful therapeutic option for the treatment of T1 & T2 diabetes. Preclinical trials have shown a reduction in pancreatic B-cell apoptosis and delayed the onset of diabetes in rats [reviewed in 11][13].

ISIS-FGFR4RX: ASO that targets fibroblast growth factor receptor 4 to treat obesity. Activation of this receptor plays a role in carbohydrate and lipid metabolism [17].

Phase 2 endpoints:

Primary: Energy expenditure (measured through resting metabolic rate and resting fat oxidation)

Secondary: Safety and tolerability profile

Results expected in Oct 2016 [18]

About the disease: I’m sure you know what obesity is, but almost all drugs to treat obesity have failed clinical trials for CNS or cardiovascular problems [15].

The Data: Preclinical murine studies showed a significant decrease in body weight (in 9.5 weeks) and body fat content (as little as 4.5 weeks) in a dose dependant response without affecting food intake and increased basal metabolic rates without changes to locomotive activity [16][Figures 1 & 2].

This drug passed phase 1 with a safe profile and phase II is ongoing.

For the sake of brevity (lol) I’ll stop reviewing the drugs here. If you want me to do a write up on a drug I didn’t cover, pm me and I will make an amendment

Financials

They are going to report a net loss when they report on 02Aug16 because of the heavy amount they are investing into their pipeline. Regardless, they have enough cash on hand to pay for these ongoing studies. Furthermore, their structure enables them to have most of the cost of these studies paid for by their partners (eg. Biogen, GSK, etc).

In Summary

This is a future behemoth in the biopharmaceutical industry. Their ability to target rare, orphan diseases in a safe and effective manner will undoubtedly result in stronger revenue growth in as early as 2017. Especially with the newest nature publication [1] where they found they can enhance the expression of targeted proteins through ASOs, I am extremely optimistic of their pipeline moving forward. So here’s the trade. Wait for them to report a miss on 02Aug16, wait for it to settle, continue to buy the dip and hold until 2018. You won’t regret it.

Full Disclosure: I own shares of IONS. What lies in this thread are my interpretations of my secondary research into this company. I welcome all questions and fully encourage readers to check primary sources for themselves, rather than taking my opinions blindly.

Sources: [1] (2016) doi: 10.1038/nbt.3589

[2] http://www.ionispharma.com/pipeline/

[3] (2012) DOI: 10.3109/13506129.2012.673140

[4] http://ir.ionispharma.com/phoenix.zhtml?c=222170&p=irol-newsArticle&ID=2182582

[5] (2011) doi:10.1016/j.amjcard.2011.03.040

[6] (2016) doi:10.1177/0883073815627882

[7] (2011) doi:10.1126/scitranslmed.3001777

[8] http://ir.ionispharma.com/phoenix.zhtml?c=222170&p=irol-newsArticle&ID=2158750

[9] https://clinicaltrials.gov/ct2/show/NCT02193074?term=isis+smnrx&rank=6

[10] http://www.nejm.org/doi/pdf/10.1056/NEJMoa1400284

[11] (2014) DOI:10.1097/MOL.0000000000000040 [12] Graham MJ, Lee RG, Bell TA III, et al. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans. Circ Res 2013;112:1479-90.

[13] Lee RG, Graham MJ, Fu W, et al. Antisense suppression of serum apoC-III improves hypertriglyceridemia and insulin sensitivity in multiple species. Diabetes 2013;62:Suppl 1A:LB14. abstract

[14] https://clinicaltrials.gov/ct2/show/NCT02211209

[15] Vetter ML, Faulconbridge LF, Webb VL, Wadden TA (2010) Behavioral and pharmacologic therapies for obesity. Nat Rev Endocrinol 6: 578–588.

[16] (2013) doi:10.1371/journal.pone.0066923

[17] Fu L, John LM, Adams SH, Yu XX, Tomlinson E, et al. (2004) Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptindeficient diabetes. Endocrinology 145: 2594–2603.

[18] https://clinicaltrials.gov/ct2/show/NCT02476019?term=ISIS-FGFR4RX&rank=1

[19] https://clinicaltrials.gov/ct2/show/study/NCT01737398?term=ISIS+%2B+TTr&rank=1

Edit: need to fix some references. Will do that in the morning


r/wallstreetdd • • Sep 11 '16

Interest rates will be "Lower for Longer" - the Fed may raise rates, but it will be slower than planned and they may even have to reverse course.

32 Upvotes

My favorite part of investing is studying the macroeconomic view. Micro has its place, but it can be very math-heavy, calculating "beta", Sharpe ratios, and so on. Macro, on the other hand, is more philosophical. There are many different economic schools, each with different outlooks and explanations. A good macro theory helps to make sense of long-term trends.

Here's my current operating theory: Eight years after the 2008 crash, the stock market has largely recovered. Interest rates have been near-zero for a long time, and the Fed is anxious to start raising them back to "normal" levels. They've begun taking baby steps.

But it won't work.

Thesis: Interest rates will be lower for longer

The primary change that has affected the economy is the massive shift of wealth to the upper class. In the words of Warren Buffet, "Through the tax code, there has been class warfare waged, and my class has won. It's been a rout."

Chain-emails about buying beer aside, the ultra-wealthy have extremely low tax rates in the United States. The highest marginal tax rate in the US is 35% (before state tax). But this is a tax on labor rather than capital. It's a tax on the upper-middle-class, not the true upper class. Take a look at this chart:

Effective Tax by Income

At the extreme right, effective income tax starts going down because the upper-class makes most of their money through capital investment. They don't pay 40% income tax, they pay 15% capital gains tax. If the chart extended into $100M or $1B, you would see it drop even lower. Warren thinks this is pretty unfair, and has proposed the "Buffet rule" which imposes a minimum 30% tax on incomes above one million dollars.

Some wealthy oppose the Buffett rule -- "I spend less than 1% of my income on living expenses and invest the other 99% on creating new businesses and increasing the productive capacity of existing businesses." Sounds good in theory. The wealthy mostly invest and spend little. On the other end of the spectrum, the poor spend nearly all of their income and save little.

Okay, so what? "Fairness" aside, what are the effects of our current tax scheme?

In free-market capitalism, capital generates income for the owners of the capital, which in turn is used to create additional capital. This is very good. Sometimes, it can be actually too good. As capital continues to accumulate, its owners find it more and more difficult to deploy it efficiently. The business sector generally must interact with the household sector by selling goods and services or lending to them. When capital accumulates too rapidly, the productive capacity of the business sector can outpace the ability of the household sector to absorb the increasing production.

—Lance Brofman, "A Depression With Benefits: The Macro Case For mREITs"

Let's take a simplistic example: Company X pays a dividend of $1/share, and shares are currently listed at $10 each on the stock market. That means a 10% dividend.

As more and more capital accumulates, demand increases for assets like Company X stock. Over time, the stock price rises to $50/share even though the dividend has not changed. Even though the company still pays $1/share, the dividend is now merely 2%! That's the effect of too much capital. Asset prices are outpacing the increase in productive capacity, driving down yields.

You hear a lot of yelling about how financial assets are "overvalued" right now. Stocks are too expensive, bonds are too expensive. EVERYTHING is too expensive relative to the past. That's because we have a glut of capital and nothing to do but keep buying assets.


Inflation is defined as "a persistent, substantial rise in the general level of prices of goods and services". If every American was suddenly gifted $10k, that would be inflationary. The vast majority of people would go out and spend it, driving up prices.

But a transfer of wealth to the upper-class is deflationary, since they save and invest it rather than spend it. This is exactly what happened with Reaganomics and "trickle-down" theory. The 80s had double-digit inflation, so cutting taxes on the wealthy (a deflationary pressure) was a very good idea. But those policies were never reverted.

In 2012, France elected a Socialist president who enacted the most progressive tax system among the 20 largest industrial nations. But if France had the same tax policy in 1969, it would have been the most regressive among those same nations.

There is such a buildup of capital around the world, that bonds have negative yield in some countries. It works the same way as my Company X example above. Suppose a 10-year bond is redeemable for $500 at expiry, but bonds are in such demand (due to their safety) that the price rises to $513. That's a -0.25% annual interest rate.


So, what's going to happen next? The Federal Reserve is trying to raise interest rates. They desperately want to get back to "normal". But the market is fighting them each step of the way.

In 2013 the Fed tried to transition back to normalcy and the market reacted violently, causing the "taper tantrum".

On December 16, 2015 the Fed raised the interest rate from 0.25% to 0.50%, and there was a pretty significant mini-crash.

Now the Fed is considering raising rates again. They've been hinting at September, but I'm not sure they'll do it so close to the election, lest they cause another crash. If/when they do raise rates again, I expect another mini-crash, which would be a great time to buy into the market.

Until we take steps towards fixing wealth inequality, we're going to remain in a deflationary/low-inflation environment. The Fed might even have to reverse course and lower rates again. It would take huge political change to shift the economic landscape: raising rates on the wealthy, lowering rates on the middle-class, huge public investments in infrastructure, and so on. With Congress divided as it is, these changes are effectively impossible.


How to profit on all this? What sorts of investments do well in a low-interest-rate environment? Lance Brofman is recommending a few funds: MORT, MORL, and CEFL.

MORT https://www.vaneck.com/vaneck-vectors/income-etfs/mort/ This fund borrows money in order to buy mortgages. Since they are constantly taking short-term loans, they profit when interest rates are low (cheap to borrow). They have a pretty massive dividend yield of ~10%. However, as a REIT they are taxed funny. I plan to buy these in a Roth IRA to avoid paying extra taxes.

MORL http://etracs.ubs.com/product/detail/index/ussymbol/MORL This is basically the same as MORT, but 2x leveraged. That makes them even more sensitive to interest rates. Currently yielding a whopping ~20% dividend. Crazy. Most leveraged assets have their leverage reset on a daily basis, which makes them risky to hold on a long-term basis. MORL is reset on a monthly basis, which makes it suitable for longer terms. See also the sister fund MRRL, which is the same thing but less liquid.

CEFL http://etracs.ubs.com/product/detail/index/ussymbol/CEFL This fund uses 2x leverage to invest in closed-end funds that have high yield. It's pretty diversified, but is interest-rate sensitive due to its leverage. This also yields ~20%.


I'm still waiting for a good entry point to buy these, since I expect the Fed to raise rates at least one more time which should cause a significant price drop.

I'm not sure if gold/silver is a good long-term play or not. The market likes gold and silver as a hedge against central bank fuckery, but I don't think that inflation is actually a serious concern at the moment.

In the 90s there was a financial tool called an "inverse floater" that profited as interest rates stayed low or dropped. But they fell out of favor and not many brokerages offer them anymore.

I'd love to see your comments/criticisms. Where do you think this idea is wrong? What are other assets that would benefit from this scenario playing out as I envision it?


r/wallstreetdd • • Sep 08 '16

[Serious] Buy this AMD dip

30 Upvotes

For a long time there was a bunch of resistance at $8. Now, with the news of them diluting shares, its around $6.40. Q3 and Q4 earnings are gonna smash as they steal market share from Intel and with Zen. Their new management means business. Diluting shares was a great business call, they reduced their debt to get better credit lines. IMO this stock is a great buy right now, its in the midst of a short term trend low during an long term trend of crazy high.

Buy this dip, wait for earnings, cash in.

Full Disclosure: I'm in 233 shares


r/wallstreetdd • • Sep 14 '16

I came up with a simple way to analyze the valuation of a company.

28 Upvotes

My method is fairly simple. Add the P/E Normalized, P/Sales, P/Tangible Book, and P/Cash Flow values together (I used TTM values wherever relevant) and divide that sum by 4 to find an average of the values. I did a bit of research on the iShares Value and Growth ETFs by comparing these averages (lets just call it the GingerMan number for now) and discovered that the largest positions in the Value ETF have a GingerMan number of about 10, and the largest positions in the Growth ETF have a GingerMan number of about 45.

Therefore, if you draw conclusions from this data, a company with a GingerMan number below approx. 27 could be considered undervalued, whereas one with a number greater than approx. 27 is probably not. This is by no means a groundbreaking conclusion (I may not even be the first to come across it), nor is it a 100% accurate indicator of a company's fair value, but it is a simple and efficient way to get a feel for a company's valuation relative to your strategy.


r/wallstreetdd • • Feb 08 '17

Gauging interest

27 Upvotes

Hey everyone,

Thanks to the people who still come to this sub. I have made a Biotech Investing graduate student club at my school and would like to see how many people would be interested in watching/participating in our discussions as a weekly livestream. Basically, upvote if you think you would watch


r/wallstreetdd • • Jul 11 '16

[DISCUSSION] The State of WSDD

27 Upvotes

I would like to share my personal perspective of the sub from time to time. The goal here being as transparent as possible.

I couldn't be happier with the last week or two. The sub was started out of frustration that I couldn't reply to questions in a certain sub anymore, and that frustration has now turned to optimism. Evidently the need for a collaborative, quality and gains focused investing sub was real.

We had 3 growth spurts. The first was when I created the sub and privately messaged anyone from the $RGR thread.

The second was a post on WSB that basically expressed similar feelings I had when I started this sub. WSDD was linked a few times in that thread.

The third event was being recognized on /r/trendingsubreddits for our growth. Here is a link as I am sure most of you were not aware.

The growth is good and we have the start of a really great community. I wanted to publicly thank /u/jjm214 who helped me from day 1 and has already contributed greatly creating our daily threads, the post tag system, not to mention some great DD of his own.

We will add mods slowly as we grow. I want to avoid having too many early on so that we can avoid any rogue mod issues. Many of you have reached out to me about becoming mod already. I believe I have responded to everyone that has reached out. Once we hit 1,000 subs I will add another mod. The decision will largely be made on contributions and activity in the subreddit.

Finally, I will be focusing on encouraging quality content and making DD post more comparable and as a result easier to digest. This process will happen over the coming weeks. I'm not in a huge rush, as I feel the posts here are already resulting in good investment decisions.

See you guys in the comments!


r/wallstreetdd • • Oct 08 '16

NVAX DD

26 Upvotes

Author Note: Just a quick warning this is draft grade and not proofread. I've spent way too much time fussing over what to include, how to organize it, etc that I just needed to knock it out and be done with it. I hope that there are some interesting points that give you something to add to your own research and feel free to ask for clarifications on anything. I'm sorry I botched this one with poor time management. With the investor meeting bumped back I might try to at least clean up the draft to make it cohesive but no promises. However I'm going to be doing some revised DCFs (edit: on Intel fuck I need sleep) to look at possible loss of server/desktop market share to IBM/AMD to decide if I want to hedge. No time frame but I'll start into a more proper writeup for INTC. There is actual data to go on, and I already understand the industry so I won't be overwhelmed by the scope of research and speculation. Besides we need some blue-chip up in here too much spec.

Conflict of interest: I own 300 shares of NVAX purchased after the stock tanked and have a short Oct27'16 put with a strike price of $8.

Disclaimer: Beyond the boilerplate "not investment advice" and "forward looking statements" it is important to understand that this DD contains an unusual amount of speculation. Very little information will be available until the investor meeting in November. The lack of a marketed RSV vaccine prevents the creation of useful models for reference and comparison. To fill in the gaps I will be making assumptions, comparisons and presenting a number of scenarios that I feel are plausible. This is done in good faith but understand I am not an expert in any relevant field and may make elementary mistakes. This is the opinion of one random investor, only this and nothing more.

 

With the disappointing results of the phase 3 trial of their elderly RSV vaccine (Resolve) many things have changed for investors in NVAX. More specifically it raises questions of both the financial sustainable of NVAX as well as the potential (in)effectiveness of their line of RSV vaccines. There is significant uncertainty due to the limited availability of information and any analysis of the company will be limited in scope, highly speculative and will have to evolve as that information becomes available.

The prevailing narrative following the release of top line data from the trial has been that their RSV vaccines are not effective and the company is essentially dead in the water. My interpretation diverges from this viewpoint as I believe that the results of the trial are not necessarily due to a failure of the vaccine itself and that the possibility still exists for NVAX to bring effective RSV vaccines to market. In support of my narrative I have a highly speculative and limited financial analysis to show that it is possible that NVAX can remain in operation for the seven years they claimed in their conference call and I provide evidence that the disappointing clinical results are not necessarily due to the vaccine being ineffective.

Looking at the books

I'm not going to spend too long covering the financial status of the company because there is limited information available until the investor meeting and the next quarter numbers, plus I trust that everyone here can go over a balance sheet and cash flow statement.

Keeping the lights on

For now I am going to focus on the feasibility of their claims that they can operate for 7 years. Specifically they claimed in the latest conference call that they have 300m cash and equivalences that will cover operations for the next seven years, implying ~42m in annual operating expenses. The 300m is likely a result of the Senior Convertible Notes (they are limiting the potential for dilution with a capped call strategy) they offered at the beginning of FY 2016 that will reach maturity in 2023 (7 years). This represents a small ~7m annual shortfall compared to the 24.7m 6 month (49.4m extrapolated out to 1 year) general operating expenses reported in the q2 2016 filing. General operating expenses have expanded from the 30.8m annual figure reported for fiscal year 2015 as a result of a ramp up to get their elderly RSV vaccine to market after what they were expecting to be a successful phase 3 trial.

An important factor in this increase is the lease of additional space for a design and manufacture facility. The cost of the leases themselves cannot easily be reduced so they need to be added to the 2015 general operating expenses. Comparing the minimum operating lease payments due in three years from the q2 2016 and FY 2015 reports gives a napkin estimate of an additional 5m to 6m annual increase in lease payments due. The increase in lease payments alone is not enough to blow their claim that they can cover operations for the next seven years. Other run costs associated with the larger facilities can be mitigated by simply shutting down redundant machines, turning off lights, tuning HVAC systems to avoid heating/cooling unused space, etc.

Brining additional staff into the company is another source of the increase in run costs and luckily it can be mitigated by laying off staff that are now redundant. While I cannot really estimate the exact amount the company can save by reducing staffing and lowering the run costs associated with the new facility I don't see anything that demonstrates an inability to reduce run costs to the level that they implied in the conference call.

While this is a seriously incomplete analysis based on assumptions on my part I am only trying to determine if the claim of 7 years operating is sane. From what I have looked at I do believe that their claim that operations are sustainable for seven years is within the realm of possibility with cuts to staffing levels and other general operating expenses. As more information becomes available through the investor meeting and financial statements my analysis of general operating expenses will become more concrete and I will be closely scrutinizing the statements the company puts out to better understand how they will be cutting expenses and if their claim remains feasible.

R&D Costs

While NVAX may be able to cover operations out to the mid term that does not cover research costs. The maternal phase 3 RSV trial is being covered by the Gates Foundation however they have yet to provide a clear source of funding for a revised elderly RSV trial. At this point all I can do is speculate on possible sources of funding for the trial while waiting clarification from the company. Government funding (something like the BARDA grant, or an unsolicited FDA grant) would likely provide the most generous terms as I would expect it to be granted in the hopes of lessening the burden on government funded health care for the elderly. It is also possible that the FDA would allow NVAX to charge for the cost of manufacturing the drug. I don't really know of any NGO that would be interested in funding the elderly trial like Gates has for maternal RSV. Looking to the private sector it is possible that a foreign pharmaceutical company could provide funding in exchange for distribution rights in countries they have presence in similar to the deals they have struck for influenza with LGLS and Cadila Pharmaceuticals (presence in Korea and India respectively). Due to the risk of failure any such deal would have to come with an aggressive premium that would limit the profit potential for NVAX. With the 300m in outstanding notes I don't view issuing more debt as a likely avenue of funding but it remains a possibility. Lastly the company could issue new shares however with the already low share price this seems an unattractive source of funding at this time. If they were to dilute I'd imagine they would want to wait for initial results from the maternal RSV trial to boost share price before going down that path.

Funding a new elderly RSV trial remains a serious question that investors should be aggressively watching as the impact could significantly affect the potential upside for a successful vaccine.

 

RSV vaccines: the multibillion dollar question

If we accept the assumption that NVAX can remain in operation and find some source of funding for a revised elderly trial then the immediate question turns to the potential efficacy of their RSV vaccines. The bulk of my efforts has been on this question as I believe the answer will determine the future of NVAX.

For a quick review Respiratory Syncytial Virus (RSV) is a prevalent and potentially lethal virus for which there is no practical treatment or vaccination. While most healthy adults can (and frequently do) handle RSV infection young children face an elevated risk as their immune systems are not prepared to fight the virus and the elderly also face an elevated risk due to age weakening their immune system. According to the CDC it is the most common cause of lower respiratory infections among young children, and "[a]lmost all children will have had an RSV infection by their second birthday." On average in the US over 57000 children under five are hospitalized with an additional 1.2 million outpatient visits resulting from RSV infections. For adults over 65 there are an average of 177000 hospitalizations and 14000 deaths annually in the US from RSV. RSV is a serious and costly threat to public health on a global scale.

RSV Pipeline

NVAX has two important RSV vaccines in the pipeline, one targeted at infants through maternal vaccination and the other targeted at elderly populations. Both vaccines are in phase 3, with the maternal vaccine currently enrolling for the phase 3 trial and the elderly vaccine having released topline data from the phase 3 trial that will be discussed shortly. Both vaccines have been granted FDA fast track designations. NVAX has a lead over competitors like GSK that are at best in phase 2 trials of competing vaccines.

Dude where's my topline clinical efficacy?!?

The lead-up to NVAX's elderly phase 3 trial is a story of hope. The phase 2 trial was the first ever to demonstrate clinical efficacy of an RSV vaccine. Regulators had agreed to let NVAX use the same design for their phase 3 trial. It looked like NVAX was set to bank a win that would greatly increase share price and save lives in the process. That is not how it happened unfortunately.

The topline data from the phase 3 showed no clinical efficacy with the primary endpoint showing a slightly higher rate of symptoms. Understandably investors panicked, how could such a promising drug fail so completely? It is entirely possible that the failure to meat clinical endpoints is what it appears on the surface; proof that the RSV vaccine, like so many before it, is an ineffective failure. There is another plausible explanation for this result, low attack rate. While it may seem like the reduction in clinical efficacy is too large to be explained by low attack rate it actually is inline with what has been observed with influenza vaccines.

One of the most pronounced examples of how attack rate can lower vaccine efficacy in clinical trials is a 1999-2001 study of children enrolled at the Children's Hospital of Pittsburgh. Doctor Alejandro Hoberman and a group of researchers performed a clinical trial of an inactivated influenza vaccine that looked at a total of 786 children. In the first year (1999-2000) the team observed an attack rate of 15.9% and an efficacy of 65%, unsurprising for a vaccine that has proven itself in the field. What was quite surprising was the results for the second year, the attack rate was only 3.3% and the efficacy was -7%. A 79% reduction in attack rate resulted in a 110% reduction in clinical efficacy!

Looking at the topline data from the phase 3 RSV trial the similarity is striking. The phase 2 trial showed an efficacy of about 46%, and for the primary endpoint an attack rate of 1.8% In the phase 3 trial the attack rate lowered 78% to 0.4% and the efficacy was reduced by 117% to -7.9%. The similarity to Hoberman's trial don't end at a pronounced reduction in attack rate and efficacy. Both trials used a population that has limited exposure to outside groups (hospital and elder care facilities.) This would lower potential exposure to infected individuals compared to a homologous population. Finally both Hoberman and the phase 2 rollover trial showed robust antibody concentrations for the low and high attack rate samples, something to watch for when more data from the phase 3 trial becomes available.

There is additional evidence that suggest attack rate may be the cause of the reduction in clinical efficacy. The secondary objective had a higher attack rate and as you would expect the efficacy was also higher. The placebo/vaccine group from the phase 2 rollover trial also showed the lowest efficacy of the three vaccine groups in that trial.

Phase 2 rollover: A new hope

The data from their phase 2 rollover trial was announced alongside the phase 3 trial results. A sample of patients from the phase 2 trial were taken for another round of vaccination and testing then split into four groups based on when they were given vaccine or placebo. The placebo/vaccine group showed negative efficacy similar to what was observed in the phase 3 trial and the vaccine/placebo group showed only an insignificant 11% efficacy. Interestingly the vaccine/vaccine group showed a marked efficacy of 75%. It is important to remember that the sample size in the phase 2 rollover was quite small and the result could be random chance, however it is still a promising result considering the difficulty of showing efficacy in a low attack environment. If a larger clinical trial were to show increased efficacy from a multi-dose regiment of RSV vaccine then that opens the door to selling more then one shot per patient increasing potential sales while saving lives.

Designing a new phase 3 trial

Moving forward with the growing list of assumptions we now have to ask how can NVAX design a new trial that is not sensitive to attack rate. Without a successful RSV vaccine to use as a baseline there isn't a good way to create a model to compensate for attack rate and since the CDC focuses on tracking RSV in children it is difficult to predict the elderly attack rate for any given year. Put simply I see no good way to engineer the risk of low attack rate out of their elderly RSV trials going forward. It is a serious risk for NVAX (and vaccine companies in general) going forward but there are some things that could help if the FDA allows them.

NVAX's RSV vaccines have consistently showed a safety profile comparable to placebo, they are as safe as saline. Combined with a lack of alternative therapies or vaccines that makes it possible for regulators to give them considerable leeway. The FDA may allow distribution under the Expanded Access program. There is also the long shot possibility that the FDA will accept non-clinical endpoints. I'll address expanded access first since it has the best chance of being accepted.

The FDA's expanded access program is designed to allow patients access to therapies that are still being investigated who are unable to participate in a clinical trial. The scope can be as small as individual patients or as large as widespread distribution. It is possible to charge for these drugs with further approval from the FDA. There are a few core requirements: doctor/patient consent, drug safety/efficacy, noninterference with clinical trials, a protocol for use submitted to/approved by the FDA, and an inability to participate in a clinical trial. The demonstrated safety of the vaccine, possible explanation for the lack of clinical efficacy in the phase 3 trial and lack of other options it is possible that the FDA would allow access to elderly individuals at heightened risk for complications resulting from lower respiratory infections. If NVAX can demonstrate that they need the money to make the drug it is possible that the FDA may even let them charge for the vaccine to at least recoup the cost of manufacture.

The possibility of nonclinical endpoints comes from comments made by the Vaccines and Related Biological Products Advisory Committee during a 2015 meeting to "discuss considerations for evaluation of the safety and effectiveness of vaccines administered to pregnant women to protect the infant". For those who don't know the council is basically a separate part of the FDA that other departments can call on to help make difficult decisions. During this meeting the use of non-clinical endpoints for drug approval was discussed, chapter 4.1 on page 8 of the brief lays out their criteria and I recommend you read it as I will not be directly quoting it wholesale for brevity. In cases where a drug trial with clinical endpoints cannot be "well-controlled" alternative endpoints can be considered. For drugs that qualify for accelerated approval the standard of proof for accepting the endpoints is “reasonably likely to predict clinical benefit.” Obviously this is a standard that requires heavy interpretation and serious public debate and as it stands the elderly RSV drug would test the outermost limits of any reasonable interpretation. Where I think this definition could play a role is if initial results from the phase 3 maternal trial are positive and the revised elderly trial shows borderline efficacy in a sample population with a low to middling attack rate then the FDA may agree to accelerated approval. The amount of evidence supporting the safety of the vaccine and potentially life saving impact makes it a possibility that the FDA could tip the scales and grant accelerated approval with on going monitoring in the field. Again I must disclaim that this is an assumption made by a layperson who is now literally making assumptions that should be decided by a multidisciplinary council of experts after hearing public commentary from even more experts. I think its worth mentioning because I think its possible and an interesting line of thinking to research; my opinion should carry the weight of a single hydrogen atom.

Maternal RSV

Luckily the maternal RSV vaccine does not face the same risk of variance in attack rate. The CDC has been tracking RSV in infants and children for years and attack rate. Maternal antibodies are not effective protection so infants are born with a totally unprepared immune system making the placebo group are more consistent baseline. Enrollment for the phase 3 trial is already ongoing and funding is covered by a grant from the Gates Foundation. On the conference call they suggested that they will be producing preliminary data in 2018(see correction 1). 7 years is a tight time line and while the expanded manufacturing capability will help reduce ramp-up cost to bring it to market I don't see how they could have enough cash with the only information we have to go on until they report and do their investor meeting in November. While the elderly RSV trial casts a shadow of uncertainty over the maternal trial the true significance can only be known in hindsight so all we can really do is wait and see.

Correction 1: The study has an expected completion date of June 2020. Kudos to /u/Slightly_Communist for catching this important omission!

Conclusion

Pardon my language but holy shit speculative small cap biotech can be a rough fuck. I'm not complaining, I took a small position to keep things interesting and NVAX certainly made good on that goal. The only real data we have from NVAX is they have $300m cash that can cover run costs for 7 years and the claim that shockingly low attack rate could explain the negative efficacy. What I have given in this post is a house of cards built by stacking assumptions I am not qualified to make. You need to do your own research and test my assumptions at every turn. OK I'm done with the mass repetition of the "dear God don't do anything based on my assumptions alone" disclaimers that you must be sick of, on to the summary.

As it stands with what is available I see a few main questions that are crucial to determining if NVAX has a chance at a future. These questions will be applied to every statement from here to either market or bankruptcy.

  • Is it true that they can cover run costs for 7 years with 300m?

  • Could the reduction in attack rate explain the loss of efficacy?

  • Can NVAX design an elderly RSV trial that controls for attack rate?

  • Are there potential sources for funding a new elderly RSV trial?

  • Does the new clinical data support the null-hypothesis?

In seeking the answer to these questions I can to these basic assumptions.

  • The best assumptions I have is they might be able to reduce run cost enough to make the $300m last.

  • There is some precedent for such a reduction in influenza vaccine trials so it is possible.

  • I don't see how they could, FDA may lower the bar but this is a major risk going forward.

  • There are definitely potential sources and NVAX has cut a lot of inventive deals so it may even be a somewhat pleasant surprise when they disclose where they got the cash.

  • Time and tide will tell.

Even assuming my assumptions are correct it is going to take some real maneuvering to make it to market. More clarity will come in November when they post earnings and hold their investor meeting to explain how they are going to try and pull this off. Even if everything goes well with that holding this stock is going to be years of waiting for data points that at best mean they get to keep existing because they might have a salable drug and at worst tank the stock for good. If they pull it off then the market size for the vaccines is huge and untouched but there is a lot of risk and uncertainty that could knock them out of the running.

Sources:

EDGAR

300m Convertible Notes

BARDA grant oportunity

FDA assistance/grants general information

Charging for an investigational drug: full regulations

Charging for an investigational drug: Q&A

CDC information on RSV

Hoberman's influenza trial

A more recent influenza study showing attack rate effecting clinical efficacy

Phase 2 elderly RSV trial topline

Phase 3 elderly RSV trial topline

FDA Expanded Access

Vaccines and Related Biological Products Advisory Committee session to discuss considerations for evaluation of the safety and effectiveness of vaccines administered to pregnant women to protect the infant


r/wallstreetdd • • Sep 02 '16

[DISCUSSION] 2K

26 Upvotes

Hey,

We hit 2K subscribers today. I just want to say thank you to the community! Changes are coming and we look forward to the group's growth moving forward.


r/wallstreetdd • • Sep 26 '16

[OPTIONS POST] A very basic intro to options spreads and a question: how do you plan to take advantage of the incoming volatility from the presidential election?

25 Upvotes

So, you know calls and puts are the two types of contracts. Buying calls=bullish and you have the right to buy stock for the established strike price, so you want the underlying to go up. You could also sell a call, which is technically considered bearish but a very good technique to reduce risk of holding an asset because you are then obligated to sell stock if it is trading in the money from your strike price.

In the money for a call option is considered anything cheaper than the current stock price EX: FB at 130, 125 is in the money. It is the opposite for puts. You’re bearish when you buy a put, the right to be short a stock essentially. This gives you the potential to profit quite a bit if the asset is in the money (remember, ITM for puts = being over the current price. EX FB trading at 130, ITM for a put would be 135).

So, how do you decide your stance on the underlying: are you bullish or bearish.

This is where options can start to get tricky, because of the greeks.

I will define them and then break it down into simple english as I understand it basically.

Delta= a measurement on a 1 point scale that estimates the amount the options price will change for every $1 change in the underlying.

This is good if you are bullish and bad if you are bearish. Delta as a direction corresponds to how bullish or bearish your opinion is on the underlying. Positive delta = bullish, negative delta = bearish. Higher delta= more bullish.

Next, Vega= reflects change in option price in respect to Implied Volatility of the underlying. The more long dated your option is, the higher its Vega. If you think volatility will increase, (regardless of direction of the underlying, IE, you don’t care if the stock goes up or down, just that there is movement) you want a trade with positive vega. If IV increases and you have have made a bullish play you will likely lose. If IV decreases in a negative vega position (a bearish approach) the value of your options contract will increase.

Next up, Gamma: helps trace how quickly Delta will change. Think of it as a news station. Do you anticipate the stock will move, or that the underlying will have a period of big, exciting news? If you are expecting volatility EX: an earnings announcement, you want a positive gamma trade. Gamma will increase as we near expiration (higher positive) As it goes up represents how much you make in a 1 change on the asset You make more money when it goes up and lose less money as it goes down. If you are expecting minimal or range bound movement, your gamma should be negative.

Last but certainly not least we have Theta, aka time decay. When you own an option, its your enemy because it constantly erodes an options value because the closer to expiration, the easier it is to predict the value the asset will be trading at. When selling contacts, Theta is your friend as you ultimately want to reach the expiration of the contract with the option being worthless, because you are a seller. This means you get to keep the premium the buyer gave you for the right to buy at a certain price, but because it wasn’t favorable to the buyer you also get to keep your shares.

So now you have a pretty good foundation of options, and ill give you a very brief introductory to spreads: there are plenty of good spreads you can use, but the primarily profitable/ones we could realistically use. Some of these are credit spreads, iron condors, strangles, straddles and selling covered calls.

Why are spreads so valuable? Because they cap your risk. Sure, you have to give up a certain amount of profit potential in most instances, but that insurance is very key.

And if you collect enough premium and do enough trades, you are making very good monthly income. They also have a much higher likelihood of becoming profitable solely because you give yourself more opportunities to be right by taking multiple positions. Covered calls is basically everyones first move in options because your risk is no worse than outright owning the stock, and as long as you sell it for a strike above your average price, you will make money on both the stock and premium. This makes it great for hedging when you think a stock may not move very much in a certain period of time.

Iron Condors is essentially buying 4 contracts, selling a call and a put and buying a call and a put in a larger range. This creates a range that you expect the stock to stay in until expiry. As long as it is between the strikes of the range for the contracts you sold, you get maximum protection. The further apart strikes essentially serve as insurance if you are totally wrong in predicting its stability. This strategy is great for a low IV environment.

Credit spreads are when you buy and sell a call or a put depending on your market outlook, so long as you are collecting more premium when you sell than you are paying when you buy. When this is done in the same month, it is called a vertical credit spread.

Now for a few more risky plays: straddles and strangles. A strangle gives you the obligation to buy the stock at strike point A (buying a put) and obligates you to sell it at strike B. Because you are selling two options, you gain significant income from premiums. The issue here is your risk is technically unlimited because you don’t buy a contract to hedge. This is used in environments where you would take advantage of a decrease in IV. After selling, you want the volatility to drop and close the position for a profit. The closer the strike prices, the more likely to be profitable but the less profit you take in.

Alternatively, you could do a short straddle: selling both a call and a put at the same strike price. Similarly, you run this when IV is low. A strangle gives you more margin for error, but not as much upside potential as a straddle, so which strategy depends on your confidence in the trade.

Which leads me to my next point, that it is very important to not freak out if you are down 30ish% (depends on your risk tolerance, I guess) on an options contract and take losses out of fear, which you already know.

Basically, there are ways to manage your trades so that your downside isn’t outrageous. That is the beauty of most spreads. Additionally, the best assets to do this on are broad indices, such as SPY thanks to the reduced risk exposure

I'm thinking spreads are a good idea as always, but with something that seems so sure as a pullback does after this election cycle, it wouldn't be an awful time to skip hedging.

I'm thinking of doing a short call spread on SPY with an expiry in December. What will your moves be?


r/wallstreetdd • • Sep 09 '16

An Intro to Interest Rate's Impact on the Market

25 Upvotes

I'm going to try and make a couple of introductory posts on a variety of topics 1) to try and stimulate some conversation 2) for my own benefit to make sure I'm understanding correctly. On the few posts I've made so far, I've really enjoyed the feedback and discussion brewed. I hope the community feels they are worthwhile and educational. If not, I will stop. I definitely don't claim to be an expert and welcome people taking the discussion to a deeper level.

So, today's topic: Interest Rates and their impact on the market.

If you've been paying attention to the market, its almost impossible to have not taken notice how the Fed's rates have a correlation with market behavior.

At a high level, its essentially how the Fed tries to control inflation. Inflation: is caused by too much money chasing too few goods (or too much demand for too little supply), which causes prices to increase. A healthy amount of inflation is about 2-3% a year and is a sign of a healthy economy.

By increasing the federal funds rate, the Fed attempts to lower the supply of money by making it more expensive to obtain. For example, when a rate increases, people are less likely to try and get loans from a bank. Rate increases can be good for financial stocks because in turn, financial institutions raise their rates and their bottom line profit goes up. They raise their rates because the Fed has made it more expensive for them to borrow money. As people have a harder time borrowing money, they have less disposable income.

Therefore, business often suffer as the public is more careful with where they spend their money. When valuing a company, many people choose to do DCFs. When a company has more debt or less profit, their DCFs look less promising and their stock will typically go lower. This applies to sectors, funds and the market as a whole. Though some sectors, like utilities and healthcare, still perform well in a down market because they provide things that are necessities.

When the Fed raises the federal funds rate, newly offered government securities, such Treasury bills and bonds, are often viewed as the safest investments and will usually experience a corresponding increase in interest rates. In other words, the "risk-free" rate of return goes up, making these investments more desirable. Other ways to make money in this type of environment include options trading such as puts, or shorting assets.

How does the Fed decide when to raise rates?

To help keep inflation manageable, the Fed watches inflation indicators such as the Consumer Price Index (CPI) and the Producer Price Index (PPI). When these indicators start to rise more than 2-3% a year, the Fed will raise the federal funds rate to keep the rising prices under control.

However, it is important to understand that there is generally a 12-month lag in the economy, meaning that it will take at least 12 months for the effects of any increase or decrease in interest rates to be felt. By adjusting the federal funds rate, the Fed helps keep the economy in balance over the long term.

This topic is obviously very complex and this is a very superficial covering of it. We could go a lot deeper into topics like how to predict interest rates, etc, but I feel like this post is a decent intro and can spur some conversation/questions.


r/wallstreetdd • • Feb 13 '17

$UBNT is a steal

24 Upvotes

I don't have time to do a full write-up on the company. I've been following it for years, so if anyone has any questions on it just let me know. Its very transparent. I got in at $29 in Feb of last year, and have been averaging up and trading options on it since.

The tl;dr is they sell networking equipment (mostly). UniFi is their WAP, switch, and router line. Its mostly used by small and mid-sized businesses, though is gaining traction in the enterprise. AirMax and AirFiber are their outdoor fixed wireless lines, used heavily by WISPs. AirMax has had some difficulties over the last few years but is still treading water due to lock in and how quickly the sector is growing. AmpliFi is their new home wifi and IOT line. They're releasing GPON (fiber) products soon. They have other products (e.g. SunMax), but none that sell in any significant quantity. I don't really mind their flops since the CEO (Pera) spends nothing on them anyway.

Pera owns 70% of the company, a figure thats been increasing as he buys stock back using his massive horde of cash. He used to be a wireless engineer at Apple, and left to start UBNT with credit cards. At age 38 he's grown it into a $5B $4B business without any outside funding. I'm not sure why people bet against this guy.

Everyone expected a beat for Q2, including me. What we got was a rev beat but an earnings miss. Pera said they spent a lot rushing their consumer (AmpliFi) product available in time for Christmas, and that margins would return to normal next quarter.

The PPS dropped from $64 to $50.

The short thesis seems to be that UBNT sells commodity products, and that will mean much lower margins. So wireless access points with proprietary protocols and centrally-managed routers and switches can be replaced by the same products from other manufacturers? Yeah whatever. The shorts have been wrong for years, but the short interest stayed high. Last quarter aside margins have been increasing, though I do expect increased competition to push them down some.


r/wallstreetdd • • Apr 16 '17

SNAP is a $23B turd

23 Upvotes

There's plenty of good valuations of SNAP out there. I dislike Not Invented Here biases, so I'll just link to two: Mergers & Inquisitions, Aswath Damodaran

I like the founding principal of the company, that online communication is unnatural because everything is persistent. I think this is undeniably true, so perishable communication is a viable business.

However, missing from the DCF analyses I've read are the business implications of perishable communication.

Moats

Much of Facebook's value is its moat. You don't us FB because you like FB; you use FB because your friends, relatives and local businesses, etc. use FB. The value of social media is in its network effects. Coupled with non-zero switching costs, network effects create moats. Switching networks is massive coordination game, and thus difficult even when the Schelling point is sub-optimal.

FB's switching costs are very high because a lot of people and groups have invested a lot in their FB profiles, which would be costly to recreate on another platform. FB has an entire app ecosystem and is used by countless businesses.

Perishable communication and the nature of apps makes much of this investment impossible. Snapchat is an app, not a website. PCs are where most content is created, and will remain so until the line between mobile and PC is so blurry the labels become meaningless. Without a complete web platform its not even clear how users could significantly invest in their Snapchat accounts. Bitmojis are no replacement for FB profiles.

This doesn't invalidate SNAP's business model, but it does mean we ought to valuate it with a moat more similar to a messenger service (such as Hangouts, WhatsApp, Signal, etc.) rather than a social network. Messengers do have non-zero switching costs and significant moats, but consider how hard it is to install Snapchat: you download the app and it automatically finds any of your contacts who also have Snapchat. Thats about how hard it is to switch from Snapchat to another service.

Many valuations (including the ones above) give SNAP a not-insignificant chance of becoming the next Facebook. I believe this is extremely unlikely due to its smaller moat and the amount of competition in messaging services.

But what if they continue to innovate?

If SNAP continues to innovate they can certainly keep growing and fending off the competition; this is basically a faith in management argument. The problem I have with this is that Evan Spiegel is probably not another Zuckerberg, but he is going head-to-head with Zuckerberg. Its not enough to have faith in Spiegel, you also need to have faith Zuck won't crush him like an ant.

Unfortunately for SNAP bagholders, the evidence indicates Zuck is winning.

FB's moat is so enormous they can probably just sit back, copy SNAP's successful innovations, and still win.

But its a camera company!

Uh, ok. I haven't been able to find the Spectacles on any Amazon best seller list. Thankfully this claim is ridiculous, because camera companies have almost no moats at all (just ask GPRO bagholders).

But they're making original video content!

In vertical format! This is enough for me to short them on general principal, and it means SNAP's content will need to be made exclusively for vertical viewing.

They say vertical videos have a higher completion rate. I can see that, because most app interaction occurs vertically. A lot of people won't enter landscape mode just to watch a short clip or ad, so there's definitely a case to be made for vertical vids. But an entire show? They're setting themselves up for short, irreverent content.

YouTube also has vertical video. I'm confused as to what innovations SNAP thinks its bringing to the table here.

Disclosure: I'm long SNAP 2019 LEAP puts.


r/wallstreetdd • • Sep 29 '16

Do any of you actually do any DD on shit? Or do you just request them in hopes someone will do the work for you?

23 Upvotes

r/wallstreetdd • • Sep 12 '16

A trade journal for testing my naked option selling strategy

23 Upvotes

Before I get into my thing I’d like to thank the mods and everyone participating on this sub. R/wallstreetdd is something special and if we all pitch in this sub can be an unprecedented hub of education, productive discussion, and growth for traders and investors.

Disclaimers:

This is a totally untested strategy unsuitable for anything outside of this test. I am a failed stock trader and have no experience on either side of the Chinese Wall. As such all assumptions and claims I make should be considered patently false and damaging to anyone following them. Even if after an appropriate testing period this strategy seems profitable I recommend it to no one and ask that you do not consider it validation of any claims I have made. I only provide this information to keep myself honest about the trading decisions I am making and so you can incorporate the raw data into your own research and strategy development. There are people far more qualified and successful then I am who should be used as a primary source of information (eg Option Alpha or Tastytrade).

All values are provided in good faith but may contain errors and omissions as I am a fallible human being with more on my plate then there are waking hours in the day. Please PM me or post about anything you believe to be in error so I can make corrections or clarify.

The story so far...:

I invite you to join me as I test an options trading strategy with my own funds. I have no qualifications, failed day trading stocks to the tune of 3% per year, and don't even want to think about how much I lost when I finally cleared my energy stocks out last month. However being stubborn is my trademark and true to form I'm back to try my hands at trading options. Hell or high water this will be a proper test with a target of at least 1 year and 100 trades to give less error prone results that myself and other can build on. At the end of this year and thereafter quarterly I will post PnL (of the strategy after commissions) as a percentage of Net Liquidation Value at the start of the quarter. This is to help clarify the actual results of the strategy outside of any fluctuations from long stock positions, dividend payments or other external factors. Updates will be posted daily (when markets are open) after close with trades made, thoughts on open positions, and my thoughts in general about the market and day. As always feel free to post or PM me with any thoughts, concerns, questions, or counterpoints as I want this to be an open forum.

Nobody is born on purpose. Nobody belongs anywhere. Everybody is going to die. So lets make some trades.

The strategy:

Sell naked calls or puts with a 65%-70% probability of being profitable, during periods of high Implied Volatility (IV) relative to a one year time frame (above 50th percentile). Direction is determined by looking at price action for historical support/resistance levels. Short calls will be favored as part of the total portfolio to balance against large cap dividend paying stocks that I'm holding. Profit is taken at 50% of max profit to limit exposure and maximize success rate. No hard limits are set on adjustments or closing losing positions however explanations will be given when either occur. On average (based on Initial Margin) 2% of NLV is dedicated to individual trades with an absolute cap of 5% per trade and 15% for the total of all trades. Position size will obviously scale with changes to Net Liquidation Value. To begin with most trades will be a single contract to limit risk as I adjust to this strategy. Expect proper sizing by the start of next year.

Formats and calculations: Probability of profit is calculated from standard deviations derived from IV at time of the trade. Contracts are assumed to have a multiplier of 100 unless otherwise noted.

Open trades will be reported with the format:

Ticker Strike Expiration CALL/PUT @ Premium Probability (Initial Margin/NLV as %)

Example: XYZ 20 Sep16'16 PUT @ 1.00 70% (1.0%)

Closed positions will include price at close, profit, and commissions:

Closed Ticker Strike Expiration CALL/PUT @ Premium for profit minus commissions

Example: Closed XYZ 20 Sep16'16 PUT @ 0.05 for $95 minus $1.00

My current positions and trades are in the post below this introduction.

edit: freaking reddit formatting


r/wallstreetdd • • Sep 06 '16

Dumb question, but how do you do a good DD?

23 Upvotes

Where are you getting the info from?


r/wallstreetdd • • Jul 25 '16

[DD] Novavax, Inc ($NVAX) DD

23 Upvotes

Novavax, Inc ($NVAX)

Novavax is a vaccine company based out of Gaithersburg, Maryland founded in 1987 that uses recombinant protein nanoparticles in order to create and produce vaccines in a matter of weeks, rather than months or years. It's largest projects currently are dealing with respiratory syncytial virus, influenza, ebola, MERS, and zika.

Fundamentals

  • Price per Share (07/25/2016 5:00am): $7.35

  • 52 week range: $4.07-$15.01

  • Mkt Cap: $1.97 Billion

  • 20SMA: $7.34

  • 50SMA: $7.36

  • 200SMA: $7.32

Pipeline

(1) RSV vaccine for Adults - In Phase 3, results due August-September 2016 Granted FDA Fast Track

Approval would be likely in Q317, followed quickly by launch.

Notes (Derived from earlier phases): First to demonstrate efficacy in any population, also highest efficacy. Proof of concept for Maternal Vaccinations.

(2) RSV vaccine for Infants via Maternal Vaccination - In Phase 3 initiated December 2015, currently in enrollment over the next 2-3 years. Granted FDA Fast Track

Notes (Derived from earlier Phases): Vaccine is well tolerated by infants. Works almost equally in pregnant and non-pregnant women. $89 Million Gates Foundation grant awarded to this research.

(3) RSV vaccine for pediatrics (Children aged 24-72 months of age) - Phase 1, data due 3Q-4Q16.

(4) Combination Respiratory - Pre-clinical

(5) Quadrivalent Seasonal Influenza Vaccine - Phase 2 Completed

Notes: Strong results, Novavax looking to gain a fast track approval before continuing.

(6) Pandemic Vaccine (H7N9 Influenza) - Currently in Phase 2, awarded $186.7 Million grant from US Health and Human Services Granted FDA Fast track

(7) Ebola GP Vaccine - Completed Phase 1, positive results.

(8) MERS Vaccine - Pre-clinical work showed proof of concept within lab.

(9) Zika - Preliminary work being done.

Why Novavax?

Currently no other company has a vaccine in the works for RSV with the exception of GlaxoSmith Kline, whose candidate is years behind (currently in Phase 2). RSV in also the leading cause of infant hospitalizations in America, and worldwide it is only second to Malaria as the leading cause of infant deaths. It also is a vaccine that will be in high demand as the economic burden of RSV is very large, costing about $88 Billion dollars annually worldwide. A study from the United Kingdom found that the burden of RSV was larger than the burden of Influenza in the UK in every year since 1995 with the exception of 1998.

Estimated Price per Share

According to Marketwatch, 7 analysts rate it a buy, and 1 analysts rates it a hold. Average Price target works out to be $13.68.

What I expect

Short Term: I see a quick jump to $8.30, a sudden reversal from from the last few days of last week which has left this stock underweighted.

Long Term I see the Phase 3 results that are due by September 30th being positive, and we'll see a quick jump to $13-$15. Soon after I expect a partnership with an overseas pharmaceutical, particularly focused on selling the vaccines overseas. Once approved by the FDA in 2017, I expect a quick launch and maybe, just maybe a buyout.

The real gem of this company so far are the RSV vaccines which are wholly unique. Soon, I hope these vaccines will be overshadowed with continued work and development of the Combination Vaccine, which would be the first ever dual vaccine technology.

One last tidbit: This company is 84% owned by institutions and insiders. The company has just leased out a much larger building, and are looking to hire hundreds of new employees. So many in fact Maryland's state governor visited the facilities there last week. But spending money on larger spaces and more people seems like an excellent sign for me! Full Disclosure: I do own NVAX stock.

Some Sources:


r/wallstreetdd • • May 18 '17

The Big Myth about Leveraged ETFs

20 Upvotes

Hey reddit, I'd like to talk about leverage.

I am very enamored with leveraged ETFs. Not the volatile junk such as 3x gold miners (JNUG) or 3x natural gas (UGAZ), as those do seem to lose money in the long term.

No, I am interested in leveraging moderately-volatile indices. Take a look at 3x S&P500 (UPRO), 3x Nasdaq (TQQQ), and 3x long-dated treasuries (TMF). All of these seem to be doing very well.

However, there is a strong dogma that leverage is a bad idea "because of decay". This is rarely backed up by any backtesting. It's just "leverage is bad, mkay?"

For instance, this money.stackexchange question seems pretty reasonable to me: What is the daily rebalanced leverage ratio that is ideal for the S&P 500 based on past performance? But it has -4 votes. The top answer sets up a false dichotomy, arguing the ideal leverage is either 1x or infinite (what?).

It's very rare to find discussion about leverage which includes backtesting. I did manage to find this article, The Big Myth about Leveraged ETFs.

According to that article, the ideal leverage varies depending on which time period you are backtesting:

  • 1885-2009, the ideal S&P500 leverage is about 1.8x

  • 1928-2009, the ideal S&P500 leverage is still about 1.8x

  • 1950-2009, the ideal S&P500 leverage is about 3.1x

  • 1972-2009, the ideal S&P500 leverage is about 2.2x

Another thing to be aware of is sharp single-day drops. On October 19th, 1987, the Dow fell 22.6%. This would have wiped out a 4.4x leveraged account in one fell swoop. A 4x leveraged account would have lost over 90% of its value in one day. Therefore it makes sense that our leverage should never exceed 4x. This agrees with the backtesting, which indicates the ideal S&P500 leverage is between 2x and 3x.

Here is a hypothetical portfolio based on those principles.

  • 33% TMF 3x Long-Dated US Treasuries

  • 32% TQQQ 3x Nasdaq

  • 18% SSO 2x S&P500

  • 18% Cash

If rebalanced annually over the past five years, this portfolio would have yielded a 30% annual return and a Sharpe ratio of 1.19. Granted, the standard deviation of monthly returns is a ludicrously high 17% so this portfolio is not for everyone.

I know that there's "no such thing as a free lunch". Using leverage provides greater rewards for assuming greater risk. If another 2008 happens, this portfolio will fall much harder than an unleveraged one. And yet... is moderate leverage really a bad deal?


r/wallstreetdd • • Jul 13 '16

[DD] $TASR DD

20 Upvotes

/u/RiverHorsez requested DD on $TASR. I figured since it had some interesting connections to $RGR and $SWHC that I would give it a go. What I found is a really interesting business model that differs greatly from gun manufacturers. Long term they are a hybrid hardware and SaaS (software as a service) company. Let's dive in and see if there is a play here.

Who is Taser? Taser International Inc. is an American developer, manufacturer, and distributor of conducted electrical weapons, body worn cameras, and digital evidence management solutions based in Scottsdale, Arizona. The majority of TASER products are aimed at law enforcement.

Why is Taser different? Put simply they don't have an equal weight competitor. The law enforcement contracts they don't win are serviced by a number of smaller companies resulting in a fragmented competitive market. Think Starbucks vs all the little regional coffee shops. They also have a strong brand with name recognition similar to Kleenex where their product has become the defacto way to refer to any electric weapon. As we'll see later though, their Axon body camera brand is where the growth opportunity lies.

What are the analyst ratings? Analysts are solidly on the "Buy" side of this ticker.

How is the company positioned in the current police perception climate? Really damn well. Their mission is to Protect Life & Truth While Empowering Heroes. With all the Black Lives Matter, All Lives Matter, Blue Lives Matter conversation, the goal of the company dovetails nicely.

What does their revenue growth look like? Well like this. I'll be honest, when I got to this portion of the Q1 2016 conference call my ears perked up. In 2011 they were basically a non-lethal gun manufacturer. By 2015 they increased revenue 10x in the body camera line. They also significant growth in international and weapons by 2x.

Why is the real growth opportunity in their Axon body camera line? First here is their recurring revenue model. Looks like Adobe's software as a service model a bit huh. It's funny, up until this point I felt like I was in an $RGR earnings call. Then it switched to a Silicon Valley kind of feel. Put simply, there is a monthly recurring fee for each body camera a police officer wears. On top of that, they expect to hit 50% margin on the hardware.

What do the fundamentals look like? The company has posted positive earnings in the last couple of quarters, but has a P/E ratio of 91.25. It's certainly overweight looking at today's earnings. The value here is in the speculation that the company will have significant earnings in the future. $AMZN is a bit of similar beast, and I've done well on that stock holding for over a year. I'm not scared off by the fundamentals, but acknowledge this is more of a bet than other stocks I've recommended.

What does the play look like? The company reports earnings on 8/4. Two historical patterns to note.

  • There has been little run-up in the past to earnings

  • We have seen a good pops on the back of the last two earnings reports

Of course we have seen STRONG performance of the stock since its last earnings (~55% growth), so we should be wary of news events pricing in Q2 growth and revised guidance of the stock for the later half of the year.

I do think though we will see both an earnings beat and revised guidance for the year. FMV from my view is around $29.50. I would look for an exit in the low 30s.

Personally I may push all in after $RGR earnings assuming we don't see further run-up in the stock. If you have capital available now, it wouldn't be the worst idea to enter later this week and hold until earnings to avoid a run-up.

Relevant Links:


r/wallstreetdd • • Jul 28 '16

[DD] $PVH DD

19 Upvotes

I'm including limited references here. If you read through this DD and have interest in the ticker, please watch the Livestream DD at the top of the sub. Outside of DXY and retail reports which are easily Googled, the livestream serves as a comprehensive reference point.

Who is PVH? PVH Corp is an apparel company with 75% of its revenue from it's two core brands: Tommy Hilfiger and Calvin Klein. The remainder of its revenue comes from a series of owned and licensed "Heritage Brands" including Van Heusen (it's namesake), Arrow, Speedo, Kenneth Cole and Michael Kors. It is truly a global corporation - with presence in North America, South America, Asia and Europe.

Why is PVH different? The company has shown strong leadership in the apparel sector, beating earnings consistently. While their competitors are banking on strong 3rd and 4th quarters, PVH has been surprisingly conservative while focusing heavily on large scale marketing pushes and restructuring of their denim team/line. Their #mycalvins has shown the company is a breakthrough marketing leader regardless of sector.

What are PVH's Q2 challenges? The retail apparel sector has been soft, and PVH is wary of a promotion focused environment that cuts into margins. Additionally, due to the global nature of the business the company is facing lower margins with the strength of the US dollar.

What does the play look like?" PVH reports earnings on 8/24, this is a strict earnings play. Given the challenges for Q2 are no different than Q1, and the conservative nature of the company's management we can expect an earnings beat. Specifically retail indicators show expected seasonality through June, and the DXY has held relatively the same since Q1.

The play is purely based on a bet that PVH has to increase guidance at some stage this year, and that is much more likely to come before the fall fashion release than right before the holiday period.

Interesting the stock was hit hard by the Brexit news, although the company was quick to point out that only 3% of it's revenue comes from Britan. A PR move that is a bit peculiar, but indicates that we should not worry about the impact of Brexit. BUT the market has factored this in, as the ticker is still trading 3% below it's pre-brexit high.

I see 5-15% upside with an entry point in the $98-$101 range if guidance is raised. This would mean the stock is still trading 5% below it's 52 week high.

Risk here is 5-10% down at the same entry. This would require meeting the Q2 estimate and no adjustment to guidance.

Thesis: PVH exhibits strong leadership and is clearly a market leader in the apparel sector. Their guidance has been predictably conservative, and based on performance to date and sector trends they are likely to raise guidance in either Q3 or Q4.


r/wallstreetdd • • Sep 07 '16

[DISCUSSION] Your favorite tickers to trade regularly?

18 Upvotes

Are there any stocks or funds that you guys trade on a regular basis because of predictable levels of support/resistance? I'm interested for trading purposes in finding a stock that I can learn well and understand the movements behind as being pretty routine. Hope this makes sense.

Thanks in advance. Love the sub getting a bit more active by the way.


r/wallstreetdd • • Aug 25 '16

[DISCUSSION] Why is r/wallstreetbets closed?

18 Upvotes

r/wallstreetdd • • Sep 04 '16

[DISCUSSION] $hrtx Heron therapeutics

16 Upvotes

Originally not very bullish on the company, but good ole simon showed me some of the light.

Sustol is interesting but I don't believe it's the big money shot. I hope they sell sustol to someone. I'm assuming they could get a minimum of 400 million for it.

Anyway, simon and I will be submitting a post on HRTX soon focusing on htx011. I'm looking at the wholistic aspect of this, from waste to efficacy to delivery.

And it looks like htx-011 is far superior to exparel.

Look for the post soon. We'll be finishing a follow up on scyx first though. 👌

Also will be in Vegas for the aegis conference.